Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.
Biotechnology producer Vertex Pharmaceuticals agreed today to purchase Semma Therapeutics, a US-based diabetes treatment developer spun out of Harvard University, in a $950m all-cash deal.
Founded in 2014, Semma is working on treatments for diabetes that will utilise billions of beta cells grown from stem cells in order to produce insulin. The cells will be infused into the liver to control glucose levels in the blood, as an alternative to insulin injections.
Douglas Melton, Xander University professor of…
